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Abstract Recently, it has been shown that the fat-derived factor
adiponectin is downregulated in insulin resistance and obesity
and that replenishment of this adipocytokine reverses insulin
resistance in mice. Growing evidence, on the other hand, suggests
that raised levels of catecholamines due to increased activity of
the sympathetic nervous system are an integral part in the
development of insulin resistance. To clarify whether catechol-
amines might exert their insulin resistance-inducing effects at
least partly via downregulation of adiponectin gene expression,
3T3-L1 adipocytes were treated with isoproterenol, and adipo-
nectin mRNA was measured by quantitative real-time reverse
transcription-polymerase chain reaction. In fact, isoproterenol
treatment reduced the level of adiponectin mRNA by about 75%
in a dose-dependent fashion with significant inhibition detectable
at concentrations as low as 10 nM isoproterenol. Furthermore,
the inhibitory effect of isoproterenol was almost completely
reversed by pretreatment of 3T3-L1 cells with the L-adrenergic
antagonist propranolol and the protein kinase A (PKA) inhibitor
H-89. Moreover, the effects of isoproterenol could be mimicked
by stimulation of stimulatory guanine nucleotide-binding (GS)-
proteins with cholera toxin and adenylyl cyclase with forskolin.
Thus, our results suggest that adiponectin gene expression is
severely suppressed by L-adrenergic agents via activation of a
GS-protein^PKA-dependent pathway. The data support a
possible role of adiponectin in catecholamine-induced insulin
resistance. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Insulin resistance is a major risk factor for diabetes and
cardiovascular disease. The factors causing insulin resistance
are still not completely understood. However, progress has
been made during the last 10 years [1]. It has become apparent
that several adipocyte-secreted factors such as free fatty acids
(FFA) [2], tumor necrosis factor (TNF) K [3], angiotensin [4],
plasminogen-activator inhibitor-1 (PAI-1) [5], and resistin [6]
can decrease insulin sensitivity in vivo and in vitro. Most
recently, two groups showed independently for the ¢rst time
that replenishment of adiponectin, also called Acrp30, GBP28
or AdipoQ, increases insulin sensitivity in di¡erent murine
models of insulin resistance in vivo [7,8].
Adiponectin was originally identi¢ed independently by four
di¡erent groups and has been shown to be a protein induced
during adipogenesis [9^12]. Hu et al. initially demonstrated
that adiponectin was decreased in murine models of obesity
and insulin resistance [11]. Recently, these studies were con-
¢rmed in humans where adiponectin is also suppressed in
insulin-resistant and obese states [13,14]. First evidence that
adiponectin is not simply a factor passively regulated by in-
sulin resistance and obesity, but actively in£uencing these
states came from studies by Fruebis et al. [15]. They could
demonstrate that a proteolytic cleavage product of adiponec-
tin increased fatty acid oxidation in muscle and caused weight
loss in mice [15]. Further support for an important role of
adiponectin in the pathogenesis of insulin resistance and obe-
sity comes from two independent genetic studies. Thus, Vion-
net et al. mapped a diabetes-susceptibility locus in a native
French cohort to human chromosome 3q27 where the gene
encoding adiponectin is located [16]. Furthermore, Kissebah
et al. demonstrated a quantitative-trait locus on 3q27 strongly
linked to the metabolic syndrome in European individuals
[17].
Together these data suggest that adiponectin is an impor-
tant modulator of insulin sensitivity in vivo. Furthermore, it
appears possible that various factors might increase or de-
crease insulin sensitivity at least partly by up- or downregu-
lation of adiponectin. In accordance with this view, Berg et al.
could demonstrate that thiazolidinedione treatment which is
known to improve insulin sensitivity increased adiponectin
expression in mice [8]. Growing evidence suggests that in-
creased activity of the sympathetic nervous system contributes
to insulin resistance [18^21]. Therefore, we hypothesized that
catecholamines might induce insulin resistance at least partly
by downregulation of adiponectin gene expression.
In the current study, we examined the e¡ect of isoproter-
enol on adiponectin mRNA expression in 3T3-L1 adipocytes
in vitro. In accordance with our hypothesis, we demonstrate
for the ¢rst time that isoproterenol inhibits adiponectin gene
expression. Furthermore, we show that this inhibitory e¡ect is
mediated via L-adrenergic receptors, stimulatory guanine nu-
cleotide-binding (GS)-proteins and protein kinase A (PKA).
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2. Materials and methods
2.1. Materials
Isoproterenol, propranolol, phentolamine, cholera toxin, forskolin,
PD 98059, SB 203580, and H-89 were purchased from Sigma Chem-
ical Co. (St. Louis, MO, USA). Cell culture reagents were obtained
from Life Technologies, Inc. (Grand Island, NY, USA), oligonucleo-
tides from MWG-Biotech (Ebersberg, Germany).
2.2. Cell culture and di¡erentiation
3T3-L1 adipocytes (American Type Culture Collection, Rockville,
MD, USA) were grown at 37‡C in 5% CO2 in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) containing 25 mM glucose, 10% fetal bo-
vine serum, and antibiotics (culture medium). At con£uence preadi-
pocytes were cultured for 2 days in culture medium further supple-
mented with 1 WM insulin, 0.5 mM isobutylmethylxanthine and 0.1
WM dexamethasone. After additional 2 days in culture medium with
1 WM insulin, cells were grown for 4 to 8 days in culture medium. At
the time of the experiments more than 90% of the cells had accumu-
lated fat droplets. Adipocytes were maintained for 6 h in serum-free
medium before various e¡ectors were added as described in the ¢gure
legends.
2.3. Analysis of adiponectin gene expression
Measurement of adiponectin gene expression was performed by
quantitative real-time reverse transcription-polymerase chain reaction
(RT-PCR) in a £uorescent temperature cycler (LightCycler, Roche
Molecular Biochemicals, Mannheim, Germany) as previously de-
scribed [22]. Brie£y, total RNA was isolated from 3T3-L1 adipocytes
using TRIzol reagent (Life Technologies, Inc., Grand Island, NY,
USA) and 1 Wg of total RNA was reverse transcribed using standard
reagents (Life Technologies, Inc., Grand Island, NY, USA). 10% of
each RT reaction was ampli¢ed in a 20 Wl PCR containing 3 mM
MgCl2, 0.5 WM of each primer and 1U LightCycler DNA Master
SYBR Green I mix (Roche Molecular Biochemicals, Mannheim, Ger-
many). Samples were loaded into capillary tubes and incubated in the
LightCycler for an initial denaturation at 94‡C for 30 s, followed by
40 cycles, each cycle consisting of 95‡C for 0 s, 61‡C for 7 s, and 72‡C
for 10 s (adiponectin) or 94‡C for 5 s, 60‡C for 7 s, and 72‡C for 21 s
(L-actin). The following oligonucleotide primers were used: adiponec-
tin (accession number U37222) AAGGACAAGGCCGTTCTCT
(sense) and TATGGGTAGTTGCAGTCAGTTGG (antisense); L-ac-
tin (accession number X03672) CCAGGGTGTGATGGTGGGA-
ATG (sense) and CGCACGATTTCCCTCTCAGCTG (antisense).
Cycle-to-Cycle SYBR Green I £uorescence emission readings were
monitored. Quanti¢cation was done by using the second derivative
maximum method of the LightCycler Software (Roche Molecular
Biochemicals, Mannheim, Germany) which determines the crossing
points of individual samples by an algorithm identifying the ¢rst turn-
ing point of the £uorescence curve. This turning point corresponds to
the ¢rst maximum of the second derivative curve and correlates in-
versely to the log of the initial template concentration. Adiponectin
mRNA levels were normalized to those of L-actin.
To con¢rm ampli¢cation of speci¢c transcripts, melting curve pro-
¢les were produced (cooling the sample to 68‡C and heating slowly to
95‡C with continuous measurement of £uorescence) at the end of each
run. The speci¢city of the PCR was further veri¢ed by subjecting the
ampli¢cation products to electrophoresis on a 1.5% agarose gel fol-
lowed by staining with ethidium bromide.
2.4. Statistical analysis
Results are shown as mean þ S.E.M. For analysis of di¡erences
between various cell treatments, unpaired Student’s t-test was used.
P values 6 0.05 are considered signi¢cant, 6 0.01 highly signi¢cant.
3. Results
3.1. Measurement of adiponectin and L-actin mRNA expression
First, the reliability of adiponectin and L-actin quanti¢ca-
tion by real-time RT-PCR was tested. For this purpose, in-
creasing amounts of total cellular RNA from di¡erentiated
3T3-L1 cells were reverse transcribed and analyzed using spe-
ci¢c primer pairs for the two genes (Fig. 1A,B). Linearity
between total RNA used per reaction and amount of
mRNA measured by the LightCycler software was obtained
in the range between 1 and 200 ng total RNA for both, adi-
ponectin (Fig. 1A) and L-actin (Fig. 1B).
3.2. Isoproterenol inhibits adiponectin gene expression
L-Adrenergic stimulation has long been known to induce
insulin resistance [23,24]. To determine whether this e¡ect
might at least partly be explained by decreased adiponectin
gene expression, fully di¡erentiated adipocytes were incubated
with increasing concentrations of isoproterenol for 16 h.
Treatment of 3T3-L1 cells with 10 WM isoproterenol reduced
the levels of adiponectin mRNA normalized to L-actin dra-
matically by about 75% as compared to untreated controls
(P6 0.01) (Fig. 2). This e¡ect was dose-dependent with a
65% inhibition already detectable at concentrations as low
as 10 nM isoproterenol (P6 0.01) (Fig. 2).
3.3. The inhibitory e¡ect of isoproterenol on adiponectin
mRNA is mediated via L-adrenergic receptors and PKA
To verify that inhibition of adiponectin gene expression by
isoproterenol is, in fact, mediated via L-adrenergic receptors,
fully di¡erentiated adipocytes were pretreated with selective
antagonists of K- (phentolamine, 100 WM) and L- (proprano-
Fig. 1. Quanti¢cation of adiponectin mRNA in 3T3-L1 adipocytes.
Total RNA from fully di¡erentiated 3T3-L1 adiopocytes was iso-
lated and subjected to quantitative real-time RT-PCR with primers
speci¢c for adiponectin (A) and L-actin (B) as described in Section
2. Data are expressed relative to adiponectin and L-actin mRNA ex-
pression measured with 200 ng RNA ( = 100%). Inset: Agarose gel
electrophoresis of the PCR products at cycle 21 (A) and 26 (B), re-
spectively.
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lol, 100 WM) adrenergic receptors for 1 h before isoproterenol
(10 WM) was added for 16 h. Adiponectin mRNA signi¢cantly
increased to about 70% of the level observed in untreated
control cells when 3T3-L1 adipocytes were pre-incubated
with propranolol before isoproterenol stimulation (P6 0.05)
(Fig. 3). Phentolamine, on the other hand, rather enhanced
the inhibitory e¡ect of isoproterenol on adiponectin gene ex-
pression (Fig. 3). Taken together, these results suggest that
isoproterenol inhibits adiponectin gene expression via L-ad-
renergic receptors.
Typically, stimulation of L-adrenergic receptors leads to
activation of GS-proteins which, in turn, activate adenylyl
cyclase and PKA. To con¢rm that the inhibitory e¡ect of
isoproterenol on adiponectin gene expression is mediated via
PKA, 3T3-L1 adipocytes were pre-incubated with H-89 (10
WM), a selective antagonist of PKA, for 1 h before isoproter-
enol (10 WM) was added for 16 h. In fact, H-89 almost com-
pletely reversed the inhibitory e¡ect of isoproterenol on adi-
ponectin gene expression (P6 0.01) (Fig. 4). Moreover, the
e¡ects of cholera toxin, an activator of GS-proteins, and for-
skolin, a direct stimulator of adenylyl cyclase, on adiponectin
gene expression were examined. As shown in Fig. 4, both
e¡ectors signi¢cantly inhibited adiponectin gene expression
by about 90%. This e¡ect was dose-dependent with signi¢cant
inhibition detectable at concentrations as low as 10 ng/ml
cholera toxin and 2 WM forskolin, respectively (data not
shown). By contrast, speci¢c inhibition of p44/42 and p38
MAP kinases by PD 98059 (50 WM) and SB 203580 (20
WM), respectively, did not rescue isoproterenol-induced sup-
pression of adiponectin gene expression (Fig. 4).
3.4. The inhibitory e¡ect of isoproterenol on adiponectin gene
expression is reversible
To con¢rm that the reduction of adiponectin mRNA by L-
adrenergic stimulation was not due to a ‘dedi¡erentiation’
e¡ect or toxic e¡ect of isoproterenol, fully di¡erentiated adi-
pocytes were treated with isoproterenol (10 WM) for 16 h and
the medium was then replaced by DMEM containing 25 mM
glucose for an additional 24 h. Incubation of 3T3-L1 adipo-
cytes with isoproterenol again decreased adiponectin gene ex-
pression to about 25% of untreated control cells (Fig. 5, col-
umns 1 and 2, P6 0.01). However, removal of isoproterenol
from the medium increased adiponectin mRNA to control
levels (Fig. 5, columns 3 and 4). Interestingly, serum-starva-
tion for an additional 24 h appeared to inhibit adiponectin
gene expression by almost 40% (Fig. 5, columns 1 and 3).
Fig. 2. Dose-dependent inhibition of adiponectin gene expression by
isoproterenol. Fully di¡erentiated 3T3-L1 cells were serum-starved
for 6 h before various concentrations of isoproterenol (Iso) were
added for 16 h. Total RNA was subjected to quantitative real-time
RT-PCR to determine adiponectin mRNA levels as described in
Section 2. Adiponectin gene expression normalized to L-actin
mRNA levels is expressed relative to untreated control cells
( = 100%). Inset: Agarose gel electrophoresis of the PCR products at
cycle 21 (adiponectin) and 26 (L-actin), respectively. Results are the
means þ S.E.M. of two to four independent experiments. **P6 0.01
comparing isoproterenol-treated with non-treated cells.
Fig. 3. Inhibition of adiponectin gene expression by isoproterenol is
mediated via L-adrenergic receptors. After 3T3-L1 cells were serum-
starved for 5 h, adipocytes were cultured in the presence or absence
of phentolamine (Phen, 100 WM) or propranolol (Prop, 100 WM) for
1 h before isoproterenol (10 WM) was added for 16 h. Total RNA
was extracted and subjected to quantitative real-time RT-PCR to
determine adiponectin mRNA levels normalized to L-actin expres-
sion as described in Section 2. Data are expressed relative to non-
treated control (Co) cells ( = 100%). **P6 0.01 comparing isoproter-
enol-treated with non-treated cells ; *P6 0.05 comparing isoprotere-
nol-treated with propranolol-pretreated adipocytes.
Fig. 4. Inhibition of adiponectin gene expression by isoproterenol is
mediated via GS-proteins, adenylyl cyclase, and PKA. After 5 h se-
rum-starvation, 3T3-L1 adipocytes were cultured in the presence or
absence of H-89 (10 WM), PD 98059 (PD, 50 WM), and SB 203580
(SB, 20 WM) for 1 h before isoproterenol (10 WM), forskolin (For,
200 WM), and cholera toxin (Chol, 1000 ng/ml) were added for 16
h. Total RNA was extracted and quantitative real-time RT-PCR
was performed as described in Section 2. Adiponectin mRNA levels
are normalized to L-actin and expressed relative to non-treated con-
trol (Co) cells ( = 100%). Results are the means þ S.E.M. of four in-
dependent experiments. **P6 0.01 comparing non-treated with iso-
proterenol-treated, forskolin-treated and cholera toxin-treated
adipocytes or comparing isoproterenol-treated and H-89-pretreated
cells.
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4. Discussion
Several lines of evidence suggest that the fat-secreted factor
adiponectin is a new insulin-sensitizing adipocytokine and
might represent a novel treatment strategy for insulin resis-
tance and type 2 diabetes [7,8].
It appears possible that various hormones mediate their
insulin sensitivity-modulating e¡ect at least partly via up- or
downregulation of adiponectin. Growing evidence suggests
that catecholamines impair insulin sensitivity and that in-
creased activity of the sympathetic nervous system contributes
to insulin resistance [18^21]. In accordance with this view, we
have previously demonstrated molecular interactions on sev-
eral levels between adrenergic and insulin signaling cascades
[25,26]. In a clinical context, our group recently demonstrated
that patients with pheochromocytoma are insulin-resistant
due to increased serum levels of catecholamines [27]. Further-
more, insulin resistance could be reduced by surgical removal
of the tumors in most cases [27]. The mechanisms by which
catecholamines induce insulin resistance are still not com-
pletely understood. In the present study, we demonstrate for
the ¢rst time that L-adrenergic stimulation decreases adipo-
nectin gene expression in 3T3-L1 adipocytes. Thus, L-adren-
ergic downregulation of this insulin-sensitizing adipocytokine
may be an important new mechanism of inducing insulin re-
sistance.
Presently, the mechanisms by which adiponectin improves
insulin sensitivity are largely unknown. Yamauchi et al. re-
ported increased fatty acid transport, combustion and energy
dissipation in muscle after adiponectin treatment [7]. These
processes lead to reduced muscle triglyceride content and se-
rum FFA levels [7]. As a result of these changes, insulin sig-
naling in muscle was improved [7]. These data suggest that
decreased levels of adiponectin may increase FFA serum lev-
els and impair insulin signaling in insulin-sensitive tissues.
Interestingly, both e¡ects can be observed in catecholamine-
induced insulin resistance. Thus, we and others have shown
that L-adrenergic stimulation leads to increased serum concen-
trations of FFA and inhibits insulin signaling molecules essen-
tial for insulin action such as insulin receptor substrates
[25,28^30]. It appears possible that reduced expression of adi-
ponectin contributes to increased FFA levels and impaired
insulin signaling after chronic catecholamine treatment. How-
ever, direct e¡ects of L-adrenergic activation on lipolysis and
insulin signaling molecules most likely also contribute [23^
25,30].
In the present study, we show evidence that the inhibitory
e¡ect of isoproterenol on adiponectin expression is mediated
via activation of PKA. These results are in accordance with
the classical view of L-adrenergic receptors being coupled to
PKA via GS-proteins and adenylyl cyclase [31]. Furthermore,
we exclude the possibility that suppression of adiponectin
gene expression is simply due to a toxic or ‘dedi¡erentiation’
e¡ect of catecholamines. The signaling pathway of isoproter-
enol downstream of PKA inhibiting adiponectin gene expres-
sion remains to be elucidated. Activation of PKA by L-adren-
ergic stimulation has been shown to stimulate p44/42 and p38
MAP kinases in adipocytes [26,32^34]. However, pretreatment
of 3T3-L1 cells with selective inhibitors of either molecule
does not rescue isoproterenol-induced suppression of adipo-
nectin gene expression. Thus, both molecules are unlikely can-
didates mediating the inhibitory e¡ect of isoproterenol down-
stream of PKA. As another possibility, lipolysis in response to
a rise in intracellular cAMP levels may play a role in the
regulation of adiponectin mRNA expression. Interestingly,
we show that starvation of 3T3-L1 adipocytes for an addi-
tional 24 h, a condition accompanied by increased lipolysis
and elevated concentrations of intracellular FFA, inhibits adi-
ponectin gene expression by about 40%.
In summary, we demonstrate for the ¢rst time that L-ad-
renergic stimulation reduces adiponectin gene expression. Fur-
thermore, we present evidence that this e¡ect is mediated via
GS-proteins, adenylyl cyclase and PKA. This mechanism may
play an important role in the pathogenesis of insulin resis-
tance and the insulin resistance syndrome. More work is
needed to clearly de¢ne the signaling pathways by which adi-
ponectin exerts its e¡ects on insulin sensitivity and to further
characterize the complex interplay between insulin, adrenergic
and adiponectin signaling.
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